| P2093 | author name string | Martin Pichler | |
| | Armin Gerger | |
| | Uwe Langsenlehner | |
| | Tanja Langsenlehner | |
| | Tatjana Stojakovic | |
| | Sabine Krenn-Pilko | |
| | Eva-Maria Thurner | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | Inflammation and cancer | Q24649640 |
| | Cancer-related inflammation | Q27860907 |
| | The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 |
| | Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions | Q33195220 |
| | Role of blood platelets in infection and inflammation | Q33344923 |
| | Platelet functions beyond hemostasis | Q33385887 |
| | The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients | Q33613591 |
| | Platelet and osteoclast β 3 integrins are critical for bone metastasis | Q33715937 |
| | Testosterone and prostate cancer: an historical perspective on a modern myth | Q34552217 |
| | NCCN clinical practice guidelines in oncology: prostate cancer | Q34616548 |
| | Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study | Q34700340 |
| | Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients | Q37279275 |
| | Molecular markers for prostatic cancer | Q37663278 |
| | Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. | Q37700375 |
| | Discovering disease-specific biomarker genes for cancer diagnosis and prognosis | Q38506525 |
| | Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis | Q44417553 |
| | Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. | Q46186672 |
| | Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. | Q53383697 |
| | Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer | Q80058778 |
| | The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases | Q80419514 |
| | Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma | Q81665959 |
| | Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up | Q82432895 |
| | Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study | Q83463354 |
| | A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study | Q84493586 |
| | Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer | Q84579629 |
| | The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas | Q86966258 |
| P433 | issue | 5 | |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| | prostate cancer | Q181257 |
| P304 | page(s) | 201.e9-16 | |
| P577 | publication date | 2015-03-11 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy | |
| P478 | volume | 33 | |